IP Library Granted Patent US 7,915,317
Granted Patent B2
US 7,915,317 · App. 10/629,308 · Granted Mar 29, 2011

Aqueous 2,6-diisopropylphenol pharmaceutical compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,915,317
App. No.
10/629,308
Granted
Mar 29, 2011
Kind
B2
Abstract

The present invention relates to aqueous pharmaceutical compositions comprising 2,6-diisopropylphenol (propofol). A composition of the present invention can comprise propofol and two or more excipients as an aqueous mixture. The propofol containing compositions are preferably sterile and are parenterally administered to any animal, including humans. The compositions are also chemically and physically stable over a wide range of environmental conditions.

Claims (25)

1. A sterile aqueous pharmaceutical composition for parenteral administration of propofol, said composition consisting essentially of about 1% (w/v) propofol and less than 15% (w/v) excipients, said excipients consisting essentially of:

7% to 9% (w/v) poloxamer component consisting essentially of Poloxamer 188;

2% to 4% (w/v) polyethylene glycol;

less than 1% (w/v) lipid;

0.5 to 2% (w/v) propylene glycol;

an antimicrobial agent; and,

a pH modifier,

wherein the composition is clear to the naked eye.

2. The composition of claim 1 , wherein said polyethylene glycol is polyethylene glycol 400.

3. The composition of claim 1 , wherein:

a) said composition has a particle size diameter of between 25 and 200 nm;

b) said composition has a particle size diameter of between 50 and 100 nm; or

c) said composition forms particles of similar particle size.

4. The composition of claim 1 , wherein:

a) said composition does not support microbial growth; or

b) said composition is microbicidal.

5. The composition of claim 1 , wherein said composition is stored in a container having a means for dispensing the composition.

6. A sterile aqueous pharmaceutical composition for parenteral administration of propofol, said composition consisting essentially of about 1% (w/v) propofol and less than 15% (w/v) excipients, said excipients consisting essentially of:

7% to 9% (w/v) poloxamer component consisting essentially of Poloxamer 188;

2% to 4% (w/v) polyethylene glycol;

0.5% to 1% (w/v) propylene glycol;

an antimicrobial agent;

a pH modifier;

and less than 1% (w/v) lipid, wherein the composition is clear to the naked eye.

7. The composition of claim 6 , wherein said excipients consist essentially of 8% (w/v) Poloxamer 188; 3% (w/v) polyethylene glycol 400; 1% (w/v) propylene glycol, an antimicrobial agent, and a pH modifier.

Assignments (3)
CHANGE OF NAME Recorded Aug 31, 2011
From: CENTOCOR ORTHO BIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 026839/0029 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2010
From: TRANSFORM PHARMACEUTICALS, INC.
To: CENTOCOR ORTHO BIOTECH INC.
Reel/Frame 024640/0616 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2003
From: ZHANG, ZHONG; ALMARSSON, ORN; CHEN, HONGMING
To: TRANSFORM PHARMACEUTICALS, INC.
Reel/Frame 014358/0767 →